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Cigarette smoking prevalence in the HIV-positive individuals is profoundly higher than
that in the HIV-negative individuals. We have demonstrated that HIV-1 transgenic rats
exhibit attenuated nicotine-mediated locomotor activity, altered cAMP response element
binding protein (CREB) and extracellular regulated kinase (ERK1/2) signaling in the
mesocorticolimbic regions. This study investigated the role of HIV-1 transactivator of
transcription (Tat) protein in the alterations of nicotine-mediated behavior and the signaling
pathway observed in the HIV-1 transgenic rats. Rats received bilateral microinjection
of recombinant Tat1 86 (25 mg/side) or vehicle directed at ventral tegmental area (VTA) 
followed by locomotor testing in response to 13 daily intravenous injections of nicotine
(0.05 mg/kg, freebase, once/day) or saline. Further, we examined the phosphorylated
levels of CREB (pCREB) and ERK1/2 (pERK1/2) in the prefrontal cortex (PFC), nucleus
accumbens (NAc) and VTA. Tat diminished baseline activity in saline control rats, and
attenuated nicotine-induced behavioral sensitization. Following repeated saline injection,
the basal levels of pERK1 in the NAc and VTA and pERK2 in VTA were lower in the vehicle
control group, relative to the Tat group. After repeated nicotine injection, pERK1 in NAc
and VTA and pERK2 in VTA were increased in the vehicle group, but not in the Tat group.
Moreover, repeated nicotine injections decreased pCREB in the PFC and VTA in the Tat
group but not in the vehicle group. Thus, these findings indicate that the direct injection
of Tat at the VTA may mediate CREB and ERK activity in response to nicotine-induced
locomotor activity.
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Introduction
Although the introduction of efficacious antiretroviral therapies reduces the mortality in HIV
infected patients, 50% of these patients still suffer from HIV-1-associated neurocognitive disorders
(HAND; Sacktor et al., 2001; Sacktor, 2002; Ellis et al., 2007; McArthur et al., 2010; Heaton et al.,
2011). Drug abuse in HIV-positive individuals results in greater neurological impairments and
precipitates the development of HAND relative to those HIV-positive individuals who do not abuse
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drugs (Del Valle et al., 2000; Ferris et al., 2008; Hudson et al., 2010;
Nath, 2010). According to the Centers for Disease Control and
Prevention (CDC) report about cigarette smoking among adults,
the rate of cigarette smoking among HIV positive individuals is
threefold greater than that in HIV negative population (CDC,
2007). HIV-positive individuals are more likely to become
dependent on nicotine and less likely to quit than HIV-negative
individuals (Hershberger et al., 2004; Fuster et al., 2009; Nahvi
and Cooperman, 2009). Several studies have demonstrated that
cigarette smoking is associated with a more rapid progression to
AIDS (Nieman et al., 1993; Crothers et al., 2005; Furber et al.,
2007; Zhao et al., 2010) and HIV-1-associated dementia (Burns
et al., 1996; Manda et al., 2010). Given the high risk for cigarette-
associatedmorbidity andmortality (Crothers et al., 2005), and the
great incidence of HAND in HIV positive individuals, there is a
critical need to define the molecular mechanisms underlying the
enhanced susceptibility to nicotine dependence in HIV smokers.
While the HIV-1 virus enters the brain and produces proviral
DNA in the early stage of HIV-1 infection (Nath and Clements,
2011), antiretroviral agents cannot prevent the production of
HIV-1 viral proteins, in the brains of HIV-1 infected patients
(McArthur et al., 2010; Nath and Clements, 2011). HIV-1
viral proteins are associated with the persistence of HIV-related
neuropathology and subsequent neurocognitive deficits (Frankel
and Young, 1998; Power et al., 1998; Brack-Werner, 1999;
Johnston et al., 2001). The mesocorticolimbic dopamine (DA)
pathway is compromised in HIV-positive individuals with drug
abuse (Kumar et al., 2009; Norman et al., 2009; Obermann et al.,
2009). Long-term viral protein exposure can accelerate damage
in the mesocorticolimbic DA system (Nath et al., 1987; Berger
and Arendt, 2000; Koutsilieri et al., 2002) and the motivation
pathway of the brain (Wise and Bozarth, 1987; Everitt and
Robbins, 2005; Berridge, 2007). Among HIV-1 viral proteins,
transactivator of transcription (Tat) protein plays a crucial role in
the neurotoxicity and cognitive impairment evident in neuroAIDS
(Rappaport et al., 1999). Tat activity is sufficient to impair learning
and memory performance (Carey et al., 2012). Tat disrupts DA
and glutamine transmission by directly interacting with the DA
transporter (Zhu et al., 2009; Midde et al., 2013) and NMDA
receptor (Li et al., 2008). Since experimental rodents cannot be
infected with HIV-1, several approaches are utilized to study
the effects of viral proteins on HIV-1 associated neurobiological
and behavioral deficits: (1) rodent brain synaptosomes and in
vitro exposure to Tat (Wallace et al., 2006; Zhu et al., 2009);
(2) direct microinjection of Tat into the brain (Harrod et al.,
2008; Ferris et al., 2010; Fitting et al., 2010); (3) transgenic
mice that express Tat protein (Kim et al., 2003; Duncan et al.,
2008); and (4) the HIV-1 transgenic rat model, which carries a
gag-pol-deleted HIV-1 provirus regulated by the viral promoter
expressing seven of the nine HIV-1 viral proteins (Reid et al.,
2001). These experimental models mimic different aspects of viral
protein-induced neurotoxicity and pathophysiological changes
in the brain, although none of these models fully represent
the spectrum of HIV-1 viral protein insult in humans. Intra-
accumbal or striatal Tat rats show decreased DA transporter
activity (Maragos et al., 2002), decreased DA levels (Cass et al.,
2003), and attenuated behavioral sensitization to cocaine (Harrod
et al., 2008). Tat transgenic mice exhibit increased DA transporter
expression (Perry et al., 2010). HIV-1 transgenic rats show
enhanced behavioral sensitization to methamphetamine (Liu
et al., 2009; Kass et al., 2010) but attenuated nicotine-mediated
behavioral sensitization (Midde et al., 2011). These studies suggest
thatHIV-1 viral proteins alter dopaminergic pathways that in part,
mediate behavioral sensitization.
Nicotine is the key component that mediates the addiction
to tobacco smoking. DA neurons in the ventral tegmental
area (VTA) and their descending projections to the nucleus
accumbens (NAc) and prefrontal cortex (PFC) comprise the
mesocorticolimbic DA pathway, which mediates the behavioral
and biological effects of nicotine (Kita et al., 1992; Panagis et al.,
1996; Laviolette and van der Kooy, 2004). Nicotine activates
nicotinic acetylcholine receptors (nAChRs) located throughout
the mesocorticolimbic DA system in the brain (Kita et al., 1992;
Panagis and Spyraki, 1996; Mansvelder et al., 2002; Laviolette
and van der Kooy, 2004). The VTA has been demonstrated to be
critical for nicotine-induced plasticity (Fu et al., 2000; Mansvelder
et al., 2002; Laviolette and van der Kooy, 2004) and play a
critical role in nicotine-mediated behavior (Corrigall et al., 1994;
Ferrari et al., 2002). The extracellular regulated protein kinase
(ERK) and its downstream transcriptional signaling protein, the
cyclic AMP response element-binding protein (CREB), appear
critical for long-term adaptations in individuals who exhibit
drug abuse (Berhow et al., 1996; Carlezon et al., 1998; Nestler,
2001; Girault et al., 2007). Acute nicotine treatment increases
CREB phosphorylation in the NAc, striatum and VTA (Walters
et al., 2005; Jackson et al., 2009), whereas repeated nicotine
treatment in mice decreases CREB phosphorylation in the NAc,
and nicotine withdrawal increases CREB phosphorylation in
the VTA (Brunzell et al., 2003). Therefore, long-term nicotine
exposure leads to neural plasticity in intracellular signaling
through the changes of ERK and CREB signaling (Brunzell
et al., 2003, 2009; Mineur et al., 2009). Our recent study shows
that HIV-1 viral proteins alter basal phosphorylation levels of
CREB and ERK and their phosphorylated response to nicotine
in the PFC of HIV-1 transgenic rats (Midde et al., 2011). Given
the critical role of the VTA in nicotine-mediated plasticity and
behavior, along with our recent report that HIV-1 viral proteins
altered ERK and CREB activity in mesocorticolimbic areas, the
current study examined whether the microinjection of Tat into
the VTA altered nicotine-mediated behavioral sensitization and
the signaling protein activity. Our results demonstrate that Tat-
induced impairment of the VTA would attenuate intravenous
nicotine-induced sensitization of locomotor activity in rats.
Materials and Methods
Animals
Male Sprague-Dawley Rats (225–250 g) were obtained from
Harlan Laboratories, Inc (Indianapolis, IN, USA). All rats
were surgically preimplanted with an Intracath IV catheter
(22 ga, Becton/Dickinson General Medical Corp., Grand Prairie,
TX, USA), which was dorsally implanted port for chronic IV
injections (Mactutus et al., 1994). Animals were pair housed in
standard polyurethane cages throughout the experiment and
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FIGURE 1 | (A) Locomotor testing paradigm and time line. (B) Body weights of
rats with the intra-VTA vehicle and the intra-VTA Tat across daily injection of
nicotine (Veh-Nic or Tat-Nic) or saline (Veh-Sal or Tat-Sal). (C) Total body weights
(mean  SEM) of rats with the intra-VTA vehicle and the intra-VTA Tat collapsed
across 14-day injections of nicotine or saline. n = 10–12 rats per group.
*p < 0.05 difference in activity between Veh-Sal and Tat-Sal groups.
provided normal rodent food (ProLab Rat/Mouse/Hamster Chow
3000) and water ad libitum. The catheters were flushed daily with
0.2 ml of heparinized (2.5%) saline. The colony was maintained
at 21  2°C, 50  10% relative humidity and a 12L:12D cycle
with lights on at 0700 h (EST). The animals were maintained
according to the National Institute of Health (NIH) guidelines
in AAALAC accredited facilities. The experimental protocol was
approved by the Institutional Animal Care and Use Committee
(IACUC) at the University of South Carolina.
Drugs
Nicotine hydrogen tartrate salt was purchased from Sigma-
Aldrich (St. Louis, MO, USA) and dissolved in sterile saline (0.9%
sodium chloride). Nicotine was prepared immediately prior to
injection. The nicotine solution was neutralized to pH 7.0 with
NaHCO3. Nicotine (0.05 mg/kg, freebase) was administered as a
bolus IV injection delivered in a volume of 1 ml/kg body weight
(15 s), and was followed by flushing (15 s) with 0.2 ml heparinized
(2.5%) saline (i.e., the approximate volume of the catheter) once
daily for 15 days. The rate of infusion is an important factor
that mediates the induction and expression of the drug-induced
locomotor sensitization. The proposed injection rate is within
the duration shown to produce robust-to-moderate behavioral
sensitization (Wallace et al., 1996; Samaha et al., 2002).
Intra-VTA Tat Microinjection
All rats received bilateral microinjections of Tat or vehicle (0.9%
NaCl containing 0.03% L-ascorbic acid) directed at the VTA
approximately 24 h after the saline baseline activity session
(Figure 1A).
Briefly, rats were anesthetized using a mixture of ketamine
hydrochloride and xylazine by intraperitoneal (IP) injection
(7.5 mg ketamine/100 g b.wt. and 30 mg xylazine/100 g b.wt.).
Rats were then be secured in a stereotaxic apparatus (David Kopf
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Instruments, Tujunga, CA, USA) where surgery was performed
under aseptic conditions. Body temperature was maintained at
37°C by a heating pad coupled to a rectal thermometer (Harvard
Apparatus, Holliston, MA, USA). An injection needle (26G)
attached to a 1-mL syringe (Hamilton Co., Reno, NV, USA) was
filled with either the Tat solution (10mg/1ml dissolved in vehicle)
or the vehicle (0.9% physiological saline) and positioned in the
VTA (A/P,  5.3 mm; M/L,  1.0 mm; D/V,  7.0 mm; bite bar,
0.0 mm). Bilateral injections (25 mg/side) of recombinant Tat1 86
were administered. The injection needle remained in position for
5 min before injection of Tat or vehicle, which was infused over a
5-min period using aminipump (Model-310; Stoelting Co.,Wood
Dale, IL, USA). The injection needle remained in position for an
additional 5 min after injection to allow for diffusion into the
surrounding tissue.
Locomotor Activity Procedure
Behavioral Apparatus
The activity monitors were square (40 cm  40 cm) locomotor
activity chambers (Hamilton-Kinder Inc., Poway, CA, USA)
that detect free movement of animals by infrared photocell
interruptions. This equipment uses an infrared photocell grid
(32 emitter/detector pairs) to measure locomotor activity.
The chambers were converted into round (40 cm diameter)
compartments by adding clear Plexiglas inserts; photocell
emitter/detector pairs were tuned by the manufacturer to handle
the extra perspex width. Total horizontal activity represents all
beam breaks in the horizontal plane. All activity monitors were
located in an isolated room.
Habituation
Ratswere randomly assigned into four groups: intra-vehicle-saline
(Veh-Sal), intra-vehicle-nicotine (Veh-Nic), intra-Tat-saline (Tat-
Sal), and intra-Tat-nicotine (Tat-Nic). All rats were habituated
to the locomotor activity chambers for two 60-min sessions,
once/day prior to intracranial injections. No injections were
administered on the habituation days. Twenty four hours after
the second habituation session, all rats were habituated to the
chambers for 30 min prior to injection, and then injected with
saline and placed into the activity chambers for 60-min tomeasure
baseline activity.
Pre-Injection Habituation and Nicotine-Induced
Behavioral Sensitization
The behavioral sensitization procedure was initiated 24 h after
intra-VTA Tat or vehicle injection (Figure 1A). First, all rats
received a 30-min habituation period in the testing chamber prior
to nicotine (0.35 mg/kg) or saline injection as previously reported
(Midde et al., 2011). This was done so that the onset of nicotine’s
effects did not overlap with the period that rats showed the
most exploratory behavior in the chamber, which was during the
first 15 min. Previous research indicates that control rats exhibit
asymptotic levels of within-session habituation by 20–30 min,
according to similar procedures and use of the same automated
chambers (Harrod and Van Horn, 2009; Midde et al., 2011). Rats
were administered nicotine or saline (i.v.) every day for a total of
14 days. Locomotor activity was assessed every other day, i.e., on
days 1, 3, 5, 7, 9, 11, and 13 for 60 min. On alternate days, nicotine
and saline administered in the home cage.
[3H]nicotine Binding Assay
The assay was conducted based on our previously published
method (Zhu et al., 1996, 2007). In brief, brain tissues were
homogenized with a Polytron in 13 volume ice cold assay buffer
containing 50 mM Tris-HCl, 120 mM NaCl, 5 mM KCl, 1 mM
MgCl2, 2 mM CaCl2, pH 7.4. Homogenates were centrifuged at
80,000 g at 4°C for 30 min. Pellets will be resuspended in the
same volume of buffer and centrifuged again at 80,000 g at 4°C
for 30 min. Final pellets were resuspended in the same volume
of buffer and the membrane fraction will be used for binding
assays. Saturation binding assays were conducted in duplicate in
a final volume of 500 mL, containing membrane homogenate
(350–500mg protein/200mL). Samples were incubated on ice with
7 concentrations (0.1–5 nM) of [3H]nicotine (82 Ci/mmol, Perkin
Elmer Life Sciences, Boston, MA, USA) for 90 min. Non-specific
binding was determined using 10 mM nicotine.
Western Blot Analysis
Following the completion of the behavioral study, animals were
killed by rapid decapitation 24 h after the last injection with
nicotine or saline on day 14, and the brains were removed and
dissected in a chilled matrix. The injection needle placement in
surgerized animals was visually assessed in brain tissue slices, and
subjects with the injection placement outside of the target region
were excluded from analysis. PFC, NAc, and VTA were dissected
and immediately sonicated on ice in a homogenization buffer
containing 20 mM HEPES, 0.5 mM EDTA, 0.1 mM EGTA, 0.4
M NaCI, 5 mM MgCI2, 20% glycerol, 1 mM PMSF, phosphatase
inhibitor cocktails I (Sigma, P2850) and protease inhibitors
(Sigma, P8340). Samples were centrifuged at 12000 g for 15 min.
The supernatant was stored at  80°C. Protein concentrations
were determined in duplicate using Bio-RadDC protein detection
reagent. Proteins (30, 10, or 15 mg per sample in the PFC, NAc or
VTA) were loaded for ERK, phosphorylated ERK (pERK), CREB
and phosphorylated CREB (pCREB) immunoreactivity.
Proteins were separated by 10% SDS-polyacrylamide
gel electrophoresis (SDS-PAGE) for 90 min at 150 V, and
subsequently transferred to Immobilon-P transfer membranes
(Cat # IPVH00010, 0.45 mm pore size; Millipore Co., Bedford,
MA, USA) in transfer buffer (50 mM Tris, 250 mM glycine,
3.5 mM SDS) using a Mini Trans-Blot Electrophoretic Transfer
Cell (Bio-Rad, Hercules, CA, USA) for 110 min at 72 V. Transfer
membranes were incubated with blocking buffer (5% dry milk
powder in PBS containing 0.5% Tween 20) for 1 h at room
temperature followed by incubation with primary antibodies
diluted in blocking buffer overnight at 4°C. Antisera against
ERK½ (V114A, Promega, Madison, WI, USA) and pERK½
(SC-16982R, Santa cruz biotechnology, inc, Santa Cruz, CA,
USA) were used at a dilution of 1:2000 and 1:1000, respectively.
Anti-CREB (9104, Cell signaling, Danvers, MA, USA) and
anti-pCREB (9196, Cell signaling, Danvers, MA, USA) antibodies
were used at a dilution of 1:1000 and 1:500, respectively. Blots
were washed 5 min  5 times with wash buffer (PBS containing
Frontiers in Microbiology | www.frontiersin.org June 2015 | Volume 6 | Article 5404
Zhu et al. Tat reduces sensitivity to nicotine
0.5% Tween 20) at room temperature, and then incubated for 1 h
in affinity-purified, peroxidase-labeled, anti-rabbit IgG (1:10000
for ERK½, 1:5000 for pERK½, Jackson ImmunoResearch,
West Grove, PA, USA) or 1:2000 anti-mouse IgG (7076, Bio-
Rad, Hercules, CA, USA) in blocking buffer for 1 h at room
temperature. Blots on the transfer membranes were detected
using enhanced chemiluminescence and developed on Hyperfilm
(ECL-plus; Amersham Biosciences UK Ltd., Little Chalfont
Buckinghamshire UK). After detection and quantification of
these proteins, each blot was stripped in 10% of Re-blot plus mild
antibody stripping solution (CHEMICON, Temecula, CA, USA)
for 20 min at room temperature and reprobed for detection of
b-tubulin (sc-9104, Santa cruz biotechnology, inc, Santa Cruz,
CA, USA). b-tubulin was used to monitor protein loading among
samples. Multiple autoradiographs were obtained using different
exposure times, and immunoreactive bands within the linear
range of detection were quantified by densitometric scanning
using Scion image software (Scion Corp., Frederick, MD, USA).
Data Analyses
The data are presented as mean values  standard error of the
mean (SEM). The body weights of rats were analyzed with a
(2  2  14) mixed factorial analysis of variance (ANOVA),
with protein (vehicle or Tat) and treatment (nicotine or saline)
as the between-subject factors, and day as the within-subject
factor. Two-factor (protein  treatment) ANOVA was used for
analyzing the collapsed body weights. A protein  day  time
(2  2  12) mixed factorial ANOVA was used to analyze data
from the two habituation days, and a protein  time (2  12)
factorial ANOVA was conducted on the saline baseline day. The
pre-injectionhabituationpartoftheexperimentwasanalyzedusing
a protein treatment day time (2 2 7 6) ANOVA. The
effect of repeatednicotine injectionon total horizontal activitywas
analyzedusingaprotein treatmentday time (22712)
factorial ANOVA. Protein and treatment were the between-
subjects factors, and day and timewere thewithin-subjects factors.
To determine the effects of repeated nicotine administration
on the activity of signaling proteins (ERK and CREB), separate
protein treatment (2 2) factorial ANOVAswere performed on
the data from the PFC, NAc, and VTA. Simple effect comparisons
were made for post hoc analyses. The equilibrium dissociation
constant (Kd) for nicotine binding and the maximal nicotine
binding capacity (Bmax) were analyzed by non-linear regression
fitting of data using GraphPad Prism 5. Differences for Bmax
and Kd values between nicotine-treated and control rats were
analyzed using an unpaired t-test. All statistical analyses were
performed using SPSS (standard version 19.0, Chicago, IL, USA)
and differences were considered significant at p< 0.05.
Results
Effects of Tat or Nicotine on Body Weight
After intra-VTA vehicle or Tat injection, daily body weights
across 14-day injections of nicotine or saline were recorded
(Figures 1B,C). A protein  treatment  day (2  2  14)
ANOVArevealed significantmain effects of protein [F(1,39)=4.2,
p < 0.05] and day [F(13,507) = 271, p < 0.001]; however, no
other main effects or interaction were significant. Subsequently,
a protein  day (2  14) ANOVA showed that overall body
weights of the intra-VTA vehicle rats were greater than that in
the intra-VTA Tat rats within saline controls [F(1,19) = 5.02,
p = 0.037, Figure 1B]. Two-factor (2  2) ANOVA analysis
revealed a significant main effect of protein [F(1,52) = 4.36,
p=0.042,Figure1C].Post hoc analysis showedbodyweights of the
intra-vehicle rats were greater than that in the intra-VTA Tat rats
[F(1,26)= 6.22, p= 0.019, Figure 1C], suggesting that intra-VTA
Tat produces a small decrease in rat body weight.
Habituation and Saline Baseline
Rats were randomly assigned to four groups: VEH-Sal, VEH-Nic,
Tat-Sal and Tat-Nic. Prior to the intracranial Tat microinjection
and nicotine injection, all rats were habituated to locomotor
activity chambers for 60 min (once/day for 2 days; Figures 2A,C).
A protein  day  time ANOVA (2  2  12) revealed
main effects of day [F(1,39) = 14.76, p < 0.001] and time
[F(11,429) = 347.79, p < 0.001]. Neither main effect of group
nor the protein  day  time interaction was significant. All
rats exhibited the most activity at first 30-min period of the
habituation session and were at asymptote for the remaining
30 min of the session (Figures 2B,D). Figure 2E shows total
activity after saline injection. Two-way (protein  time) ANOVA
revealed a main effect of time [F(11,429) = 61.35, p < 0.001].
Neither main effect of protein nor the protein  time interaction
was significant (Figure 2F).
Pre-Injection Habituation
All rats were placed in the locomotor chambers for 30 min
prior to nicotine or saline injection. Figures 3A,B show total
horizontal activity during the habituation period across the 13
sessions. A mixed-factor protein  treatment  day  time
ANOVA (2  2  7  6) revealed significant main effects of
day [F(6,234) = 28.86, p < 0.001] and time [F(5,195) = 477.02,
p < 0.001], however, no other main effects or interactions were
significant.
Nicotine-Mediated Behavioral Sensitization
The effect of Tat protein on nicotine-mediated locomotor
sensitization in rats with and without intra-VTA Tat was
determined by measuring total activity following administration
of nicotine (0.05 mg/kg, i.v.) or saline (Figures 3C,D). A
protein treatmentday timeANOVA(2276) revealed
significant main effects of protein [F(1,36) = 3.25, p < 0.05],
treatment [F(1,36) = 4.12, p < 0.05], day [F(6,216) = 23.9,
p < 0.001] and time [F(6,396) = 332.2, p < 0.001]. A significant
interactions of treatment  day [F(6,216) = 3.68, p < 0.01] and
treatment  time [F(11,396) = 3.18, p < 0.01] were found. No
significant interactions of protein  treatment and protein  day
were detected.
Subsequently, a separate three-factor ANOVA was performed
to determine the Tat effects on baseline locomotor activity
and nicotine-induced sensitization. In intra-VTA VEH
group, significant main effects of day [F(6,108) = 16.13,
p < 0.001] and time [F(11,198) = 196.75, p < 0.001] were found;
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FIGURE 2 | Locomotor activity during the habituation and the saline
baseline sessions. Rats were randomly assigned to four groups:
intra-VTA vehicle and the intra-VTA Tat rats with daily injection of nicotine
(Veh-Nic or Tat-Nic) or saline (Veh-Sal or Tat-Sal). (A,C,E) Represent the
total horizontal activity (mean  SEM) across the 60-min habituation
period. (B,D,F) Show the time course of the total horizontal activity
(mean  SEM) during each 5-min interval across the 60-min habituation
period. n = 10–12 rats per group.
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FIGURE 3 | The time-course data during the behavioral sensitization
phase. Rats with intra-VTA vehicle (Veh) or Tat were intravenously administered
nicotine (Nic; 0.35 mg/kg, Veh-Nic, or Tat-Nic) or saline (Veh-Sal or Tat-Sal) on
Days 1–13. (A,B) Shows the total horizontal activity (mean  SEM) during the
30-min pre-injection habituation period. (C,D) Shows the total horizontal activity
(mean  SEM) during 60 min following nicotine or saline injection. *p < 0.05
difference in activity between the intra-VTA VEH and intra-VTA Tat groups.
n = 10–12 rats per group.
however, the main effect of treatment was not significant. The
interactions of day  treatment [F(6,108) = 4.44, p < 0.001] and
time  treatment [F(6,108) = 4.44, p < 0.001] were significant.
Post hoc analyses showed that nicotine produced hypoactivity
on Days 1–3, but enhanced activity on Days 7–13 compared
to the respective saline controls (p < 0.05). In intra-VTA Tat
group, a three-factor ANOVA revealed main effects of treatment
[F(1,18) = 3.43, p < 0.05], day [F(6,108) = 8.59, p < 0.001]
and time [F(11,198) = 143, p < 0.001]. The interaction of
treatment  time [F(11,198) = 2.03, p < 0.05] was significant;
however, the treatment  day interaction was not significant.
Post hoc analyses showed that no effect of nicotine on activity
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on Days 1–3, but nicotine produced significant hyperactivity on
Days 5–13, relative to the respective saline controls (p< 0.05).
Furthermore, separate three-factor ANOVAs were used to
determine the differences in locomotor activity between intra-
VTA VEH and Tat groups. In the saline control group, the main
effects of protein [F(1,18)= 3.39, p< 0.05], day [F(6,108)= 6.34,
p < 0.001] and time [F(11,198) = 166.96, p < 0.001] were
significant, suggesting that Tat diminishes baseline activity
(Figure 3C). No significant interactions of protein  day or
protein  time were found. In nicotine-treated groups, the
main effect of protein was not significant; however, significant
main effects of day [F(6,108) = 20.3, p < 0.001] and time
[F(11,198) = 168.6, p < 0.001] were found. Moreover, the
interaction of protein  day [F(6,108) = 2.25, p < 0.05] was
significant. Post hoc tests revealed that nicotine-induced activity
was diminished in intra-VTA Tat rats on days 9–13, relative to
intra-VTA VEH rats (p< 0.05, Figure 3D).
A protein  treatment  day  time ANOVA was conducted
on Day 1 and Day 13 to determine the effect of intra-VTA
Tat on nicotine-induced behavioral sensitization (Figure 4). The
main effects of protein [F(1,36) = 4.04, p < 0.05], treatment
[F(1,36) = 3.0, p < 0.05], day [F(1,36) = 178.9, p < 0.001], and
time [F(11,396) = 82.02, p < 0.001] were significant. Moreover,
the interactions of protein  day  treatment [F(1,36) = 3.0,
p < 0.05], protein  time  treatment [F(11,396) = 1.84,
p < 0.05], time  treatment [F(11,396) = 3.38, p < 0.001] were
significant. On day 1, a three-factor ANOVA revealed that a
significant interaction of protein  treatment [F(1,36) = 5.24,
p < 0.05]. No significant main effects of protein and treatment
were found. Activity was lower in VEH-Nic group than that in
VEH-Sal group (p < 0.001, Bonferroni t-test). Total activity was
not different between the Tat-Nic and Tat-Sal groups (p > 0.05).
Similarly, total activity was not different between VEH-Sal and
Tat-Sal groups (p > 0.05). On day 13, a three-factor AVONA
revealed that significant main effects of protein [F(1,36) = 4.46,
p< 0.05] and treatment [F(1,36)= 6.13, p< 0.05]. No interaction
of protein  treatment was found. Post hoc analyses showed
that nicotine increased activity in both intra-VTA VEH and
Tat groups; however, the nicotine-induced hyperactivity was
diminished in intra-VTA Tat group, relative to intra-VTA VEH
group (p< 0.05; Figure 4B), suggesting that Tat disrupts nicotine-
mediated behavioral sensitization.
Intra-VTA Tat Attenuates Nicotine-Induced
Increase of [3H]Nicotine Binding in Midbrain
To determine whether intra-VTA Tat affects nAChR density,
we measured Bmax and Kd for [3H]nicotine binding in the rat
midbrain following repeated administration of nicotine or saline
(Table 1). Repeated nicotine injections significantly increased
Bmax (21%) in VEH-Nic rats (0.51  0.01), relative to VEH-
Sal rats [0.42  0.01, F(1,6) = 33.57, p < 0.01], suggesting
nicotine-induced upregulation of nicotinic receptors. However,
the nicotine-induced increase of Bmax values was not found in
intra-VTA Tat rats (0.46  0.01) compared to the respective
saline controls (0.50 0.01), indicating that Tat protein attenuates
the nicotine-induced augmentation of nicotinic receptors. No
difference in Kd values was found between groups.
TABLE 1 | Intra tegmental Tat1 86 attenuated repeated nicotine-induced
upregulation of [3H]nicotine binding sites in rat midbrain.
Veh-Sal Veh-Nic Tat-Sal Tat-Nic
Bmax (fmol/
mg protein) 0.42  0.01 0.51  0.01* 0.46  0.01 0.50  0.02
Kd (nM) 1.90  0.37 2.06  0.40 2.16  0.75 1.84  0.52
*Values differing significantly from vehicle control (P < 0.05).
ERK and CREB Signaling in PFC, NAc, and VTA
Separate two-way ANOVAs were performed to determine
the effect of Tat on total CREB and ERK1/2, and their
phosphorylation levels in the PFC, NAc, and VTA of rats with
intra-VTA Tat or vehicle. In PFC, no significant differences
in total CREB, ERK1/2, and pERK1/2 were found among the
groups (Figure 5). With respect to the ratio of pCREB/b-
tubulin, main effects of protein [F(1,32) = 13.15, p < 0.01]
and treatment [F(1,32) = 20.21, p < 0.01], and interaction of
protein  treatment [F(1,32) = 4.46, p < 0.05] were significant.
Repeated administration of nicotine decreased pCREB levels in
intra-VTA Tat rats [F(1,16) = 19.51, p < 0.01], but not in intra-
VTA vehicle rats [F(1,16) = 3.21, p > 0.01] compared to their
saline controls.
In the NAc, as shown in Figure 6, no significant differences
were found among the groups in total CREB, ERK1/2, and
pREK2. With respect to the ratio of pCREB/b-tubulin, a main
effect of treatment [F(1,36) = 14.46, p < 0.05] and a significant
protein  treatment interaction [F(1,36) = 4.17, p < 0.05] were
found. Post hoc analysis revealed that pCREB was greater in the
Veh-Sal group than that in the Tat-Sal group [F(1,18) = 4.29,
p < 0.05]. Nicotine significantly decreased pCREB in the intra-
VTA vehicle group [F(1,18) = 14.32, p < 0.01] but not in
the intra-VTA Tat group relative their saline controls. With
respect to the ratio of pERK1/b-tubulin, main effects of protein
[F(1,20) = 16.64, p < 0.05] and treatment [F(1,20) = 7.60,
p < 0.05], and a significant protein  treatment interaction
[F(1,20)= 5.59, p< 0.05] were found (Figure 6). In saline control
group, pERK1 was lower in the intra-VTA vehicle group than that
in the intra-VTA Tat group [F(1,10) = 21.96, p < 0.05]. Nicotine
significantly increased pERK1 in the intra-VTA vehicle group
[F(1,10) = 56.10, p < 0.01] but not in the intra-VTA Tat group
[F(1.10) = 0.04, p> 0.05] compared with their saline controls.
Figure 7 shows the ratio of total CREB, pCREB, ERK1/2,
and pERK1/2/b-tubulin in the VTA among all groups. Total
CREB and ERK1/2 were not different among the groups. For
pCREB, two-way ANOVA revealed significant main effects of
protein [F(1,32) = 5.64, p < 0.05] and treatment [F(1,32) = 8.67,
p < 0.01], but the protein  treatment interaction was not
significant. Following repeated nicotine administration, pCREB
was significantly decreased in the intra-VTA Tat group [F(1,
16) = 8.81, p < 0.01], but not in the intra-VTA vehicle group
[F(1, 16) = 1.30, p > 0.05] compared to their respective saline
controls. The level of pCREB was greater in the intra-VTA vehicle
group than that in the intra-VTA Tat group within nicotine
treated groups.With respect to pERK1, the main effects of protein
[F(1,16) = 15.02, p < 0.01] and treatment [F(1,16) = 9.49,
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FIGURE 4 | The time-course data for total horizontal activity
during day 1 and day 13 of the behavioral sensitization phase.
(A,B) Show the total horizontal activity (mean  SEM) across the
60-min session. (C,D) Show the time course of the total horizontal
activity (mean  SEM) during each 5-min time interval. *p < 0.05
difference in activity between nicotine-treated and saline control groups.
#p < 0.05 difference in activity between Veh-Nic and Tat-Nic groups.
n = 10–12 rats per group.
p< 0.05] and interaction of protein treatment [F(1,16)= 22.44,
p < 0.01] were significant. Post hoc analysis showed that pERK1
was lower in the intra-VTA vehicle group than that in the
intra-VTA Tat group within saline controls [F(1,8) = 59.79,
p < 0.01]. Repeated administration of nicotine increased pERK1
in the intra-VTA vehicle group but not in the intra-VTA
Tat group compared to their saline controls [F(1,8) = 26.00,
p < 0.01]. Similarly, regarding to pERK2, the main effect of
protein [F(1,16) = 6.67, p < 0.05] and protein  treatment
interaction [F(1,16) = 10.28, p < 0.05] were significant. Post
hoc analysis revealed that pERK2 was lower in the intra-VTA
vehicle group than that in the intra-VTA Tat group within
saline controls [F(1,8) = 104.90, p < 0.01]. Nicotine significantly
increased pERK2 in the intra-VTA vehicle group but not in the
intra-VTA Tat group compared to the respective saline controls
[F(1,8)= 7.84, p< 0.05].
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FIGURE 5 | Levels of ERK and CREB proteins in the PFC of intra-VTA
vehicle or Tat rats. (A) Representative western blots showing the protein
density of CREB, pCREB, ERK1/2, pERK1/2 and b-tubulin in the PFC of rats
with intra-VTA vehicle (Veh) or Tat following repeated injections of nicotine
(Veh-Nic or Tat-Nic) or saline (Veh-Sal or Tat-Sal). (B) Total and phosphorylated
levels of CREB and ERK1/2. Ratios are presented as the mean percentage of
b-tubulin  SEM *p < 0.05 difference between Tat-Sal and Tat-Nic groups.
n = 10–12 rats per group.
Discussion
The present findings demonstrate that a direct injection of
HIV-1 Tat protein into the rat VTA results in neurochemical
and behavioral alterations in response to repeated nicotine
administration. Specifically, consistent with our recent report
as demonstrated in HIV-1 transgenic rats (Midde et al., 2011),
intra-VTA Tat diminished locomotor activity under saline
control condition and attenuated nicotine-induced behavioral
sensitization. Accordingly, intra-VTA Tat decreased the basal
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FIGURE 6 | Levels of ERK and CREB proteins in the NAc of
intra-VTA vehicle or Tat rats. (A) Representative western blots
showing the protein density of CREB, pCREB, ERK1/2, pERK1/2, and
b-tubulin in the NAc of rats with intra-VTA vehicle (Veh) or Tat following
repeated injections of nicotine (Veh-Nic or Tat-Nic) or saline (Veh-Sal or
Tat-Sal). (B) Total and phosphorylated levels of CREB and ERK1/2.
Ratios are presented as the mean percentage of b-tubulin  SEM
*p < 0.05 difference between Veh-Sal and Veh-Nic groups. #p < 0.05
difference between Veh-Sal and Tat-Sal groups. n = 10–12 rats per
group.
levels of pERK1 or pERK2 in the NAc and VTA and attenuated
nicotine-mediated changes in pCREB and pERK1/2, suggesting
that ERK1/2 and CREB activity may play an important role
in Tat-induced changes in locomotion. Together, the findings
demonstrate that (1) Tat protein is critical for HIV-1 viral protein-
induced neurochemical and behavioral changes in response to
nicotine, and (2) the CREB and ERK signaling pathway in the
mesocorticolimbic system appears to have played a role in the
blunted nicotine-mediated locomotor activity by Tat protein.
The current study demonstrates that rats with intra-VTA
Tat exhibited a small decrease in body weight under saline
control condition compared to the vehicle control; however,
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FIGURE 7 | Levels of ERK and CREB proteins in the VTA of intra-VTA
vehicle or Tat rats. (A) Representative western blots showing the protein
density of CREB, pCREB, ERK1/2, pERK1/2, and b-tubulin in the VTA of
rats with intra-VTA vehicle (Veh) or Tat following repeated injections of
nicotine (Veh-Nic or Tat-Nic) or saline (Veh-Sal or Tat-Sal). (B) Total and
phosphorylated levels of CREB and ERK1/2. Ratios are
presented as the mean percentage of b-tubulin  SEM *p < 0.05
difference between nicotine-treated and saline control groups. #p < 0.05
difference between intra-VTA Veh and intra-VTA Tat groups. n = 10–12
rats per group.
this difference was not observed following repeated nicotine
injections. Of interest, our previous work shows that HIV-1
transgenic rats exhibit an inherent reduction of baseline body
weight relative to control fisher 344 rats (Midde et al., 2011). The
VTA of the midbrain is important for food consumption and
body weight (Koyama et al., 2013; Matheny et al., 2014) and plays
Frontiers in Microbiology | www.frontiersin.org June 2015 | Volume 6 | Article 54012
Zhu et al. Tat reduces sensitivity to nicotine
a critical role in food intake and reward (Mietlicki-Baase et al.,
2015). Therefore, one implication of our present findings is that
Tat-induced impairment of the DA system within the VTA may,
at least in part, result in the reduction of food consumption and
body weight noted in HIV-1 transgenic rats (Peng et al., 2010).
Although these animals exhibited a lower body weight, they are
capable of displaying behavioral sensitization (Liu et al., 2009;
Midde et al., 2011), suggesting that the HIV-associated decrease
in body weight does not prevent nicotine-induced hyperactivity
and the development of behavioral sensitization.
Regarding the behavioral portion of the experiment, the intra-
VTA Tat rats exhibited the blunted locomotor response across 60-
min behavioral sensitization phases in response to repeated saline
injections. Similarly, HIV-1 transgenic rats showed less activity
during day 1 of habituations (Midde et al., 2011) and less rearing
and headmovement activity (Liu et al., 2009), compared to control
F344 rats. The blunted locomotor activity appears to be the result
of manipulation of DA system by viral proteins (Fink and Smith,
1980), which is evidenced by an increase in D1 receptors (Liu
et al., 2009) and a decrease in DAT mRNA (Webb et al., 2010) in
the brain of HIV-1 transgenic rats. Opposite effect of D1 receptor
expression on baseline locomotor activity has been observed in
D1 receptor-deficient mice (El-Ghundi et al., 2010). Thus, these
findings further suggest that the diminished locomotor activity is
related to neural adaptations produced by Tat protein.
Following repeated nicotine administration, intra-VTA
Tat altered the induction of nicotine-mediated behavioral
sensitization, as well. First, behavioral sensitization to nicotine
was observed in rats with intra-VTA Tat or vehicle, suggesting
that intra-VTA Tat animals do not exhibit a deficit in developing
behavioral sensitization. Second, compared to saline controls,
intra-VTA vehicle rats exhibited lower acute nicotine-mediated
activity, whereas acute nicotine had no effect on activity in
the intra-VTA Tat rats. No difference in acute nicotine-induced
activity between the intra-VTATat and intra-VTA vehicle rats was
observed. However, following repeated nicotine administration,
the intra-VTA Tat rats exhibited the blunted nicotine-mediated
locomotor activity during the later days, i.e., 9–13, relative to the
intra-VTA vehicle rats. Therefore, intra-VTA Tat rats exhibited
less sensitivity to the repeated effects of nicotine, and this deficit
may contribute to a manipulation of nAChR-mediated dopamine
neurotransmission in the VTA induced by Tat protein. This
conclusion is supported by our data showing an attenuation of
nicotine-augmented [3H]nicotine binding in intra-VTA Tat rats
(Table 1). Indeed, bilateral microinjections of cytisine, a nicotinic
receptor agonist, into the VTA increase locomotor activity, which
is antagonized by either mecamylamine, a nicotinic receptor
antagonist, or pimozide, a central dopaminergic antagonist
(Museo and Wise, 1990). Furthermore, the nicotine-mediated
locomotor activity can be attenuated by ventral tegmental
6-hydroxydopamine lesions (Louis and Clarke, 1998) or by
nicotinic receptor antagonists (Clarke and Kumar, 1983).
These results suggest that a critical role of nAChR-mediated
at the level of the VTA in the nicotine-mediated locomotor
activity. Similarly, our previous research found that intracranial
injection of Tat into the striatum or NAc of rats increases
acute locomotor response to cocaine (Ferris et al., 2010) but
attenuated behavioral sensitization to cocaine (Harrod et al.,
2008). Together, these findings demonstrate that intra-VTA
Tat alters nicotine-mediated behavior, suggesting that cigarette
smoking in HIV-positive individuals produces alterations in
motivated behavior in response to nicotine due to disrupting the
mesocorticolimbic DA system by HIV-1 viral proteins.
The behavioral measure of sensitization reflects the effect of
repeated psychostimulant exposure on the mesocorticolimbic DA
system. The increase in behavior is hypothesized to correspond
to the transition from recreational to compulsive drug intake
(Robinson andBerridge, 1993; Pierce andKalivas, 1997); however,
behavioral sensitization is not a measure of drug reward.
One potential implication of the attenuated nicotine-mediated
sensitized response observed in our previous and current
studies is that cigarette smoking by HIV-positive individuals
would produce a synergistic influence on motivated behavior
due to the interplay of nicotine exposure and viral proteins
within the mesocorticolimbic DA system. One caveat is that
the current study only tests the nicotine-mediated behavior
after Tat exposure, which mimics a synergistic consequence of
nicotine and Tat protein in HIV infected tobacco smokers. This
study, however, does not address the impact of nicotine-induced
neuroadaptations occurring in the brain prior to HIV infection.
Nevertheless, the current findings, at least in part, suggest that
HIV infection in humans would produce alterations in motivated
behavior due to the changes in signaling proteins with the
mesocorticolimbic DA system. Given a high tobacco smoking
prevalence among HIV-1 positive population, we predict that Tat
exposure modulates the abuse liability of nicotine. Determining
the role of Tat protein in rodent nicotine self-administration will
be an important essential future study.
The second part of the experiment determined ERK and CREB
signaling throughout the mesocorticolimbic DA system in rats
with intra-VTA Tat or vehicle following repeated nicotine or
saline injections. First, in saline control groups, intra-VTA Tat
increased basal levels of pERK 1 in the NAc and VTA, and
pERK2 in the VTA, compared to vehicle controls, suggesting
that the impairment of dopaminergic neuronal activity induced
by Tat-mediated neurotoxicity. This conclusion is supported
by a previous report showing that methamphetamine-induced
neurotoxicity increase in pERK levels (Yan et al., 2014).
Second, following repeated nicotine administration, the intra-
VTA vehicle group showed increased pERK1 in the NAc and
VTA and increased pERK2 in the VTA; however, neither
pERK1 nor pERK in the VTA or NAc was altered in the
intra-VTA Tat rats, relative to saline controls. Nicotine has
been shown to increase the phosphorylation levels of ERK1/2
in vitro and in vivo (Nakayama et al., 2001; Valjent et al.,
2004; Gomez et al., 2015). The attenuation of nicotine-induced
pERK1/2 in the intra-VTA Tat group may represent Tat-induced
disruption of nicotinic receptor-mediated dopaminergic activity,
which is consistent with our previous observation in HIV-1
transgenic rats (Midde et al., 2011). Discrete manipulation of
VTA ERK2, using viral-mediated dominant negative mutant
of ERK2, diminished cocaine-induced behavioral sensitization
(Iniguez et al., 2010). Further, blockage of ERK1/2 activity by
SL327, a selective inhibitor of mitogen-activated protein kinase,
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prevented the induction of locomotion sensitization to either
cocaine or amphetamine (Valjent et al., 2005, 2006). In addition,
it is possible that the intra-VTA Tat rats have relatively higher
basal levels of pERK1/2 under saline control condition, which
may produce a ceiling effect on nicotine-mediated pERK1/2,
thereby covering the nicotine-induced elevation of pERK1/2 in
the intra-VTA Tat group. In accordance, our results show that
HIV-1 transgenic rat model exhibited a lower IC50 value for
[3H]nicotine binding with fivefold rightward shift of the nicotine
concentration curve in the prefrontal in the midbrain, compared
to control Fisher 344 rats (unpublished data) and attenuated
chronic nicotine treatment-induced upregulated [3H]nicotine
binding in the VTA (the current study). Collectively, these
findings suggest that long-termTat exposure can disrupt nicotinic
receptor-mediated dopaminergic activity within the mesolimbic
area, thereby reducing sensitivity to nicotine. This may, at least in
part, explainwhyHIV-infected patients need to keep smoking and
are more likely to become dependent of nicotine.
Previous studies demonstrate that acute Tat exposure in vitro
produces depolarization on neuronal membrane and increases
evoked neuronal firing (Wayman et al., 2015); however, long-
term exposure of Tat causes loss of selective populations of
neurons in vitro and in vivo (Cass et al., 2003; Maragos et al.,
2003). Furthermore, Tat transgenic mice exhibit marked glial
cell activation accompanied by neuronal loss (Kim et al., 2003).
These results suggest that Tat may initiate neuronal activity but
produces neurotoxic effect on neuronal survivals after a long-
term exposure. On the other hand, after chronic administration of
nicotine, there was no change inVTAdopamine soma size inmice
(Mazei-Robison et al., 2014); however, other study demonstrated
that exposure to nicotine in vitro increased dendritic arborization
and soma size in mesencephalic dopaminergic neurons (Collo
et al., 2013). Although there is no report about the synergistic
effects of Tat and nicotine on dopaminergic neurons, we
hypothesize that intra-VTA Tat can disrupt neuronal activity,
such as apoptosis by increasing phosphorylation of ERK activity
because the persistent enhancement of ERK activity is associated
with cell death (Stanciu et al., 2000; Kulich and Chu, 2001). Given
the beneficial outcomes of nicotine on HIV-1 infection-induced
neurological deficits (Cao et al., 2013), we speculate that acute
nicotine may be beneficial to Tat-induced neuron loss due to
Tat-induced transient increase in the neuronal activity; however,
long-term exposure of nicotine is unlikely to be beneficial in Tat-
induced dysfunction of neuronal activity, such as morphological
changes in the VTA neuron. Indeed, a recent study demonstrates
that repeated nicotine administration did not alter the learning
deficit in HIV-1 transgenic rats (Vigorito et al., 2013). Precise
conclusion about the beneficial outcome from nicotine treatment
on neurocognitive impairment inHIV-infected patients, however,
will require extensive studies of integrity of neurons and synaptic
plasticity genes in animals with Tat exposure and Tat plus nicotine
treatment.
Repeated nicotine administration decreased pCREB in theNAc
but not in PFC and VTA of vehicle controls, whereas the pCREB
level was reduced in the PFC and VTA of the intra-VTA Tat
group. However, the microinjection of Tat into the VTA did
not alter basal pCREB levels. Interestingly, our previous study
shows that repeated nicotine injection increased pCREB in F344
control rats but decreased pCREB in HIV-1 transgenic rats, these
changes were only observed in the PFC (Midde et al., 2011). The
two studies show differential brain regional sensitivity to altered
pCREB by viral proteins because two different animal models
were used. For example, Tat has higher expression in the PFC
compared to other brain regions of HIV-1 transgenic rats (Peng
et al., 2010), while direct injection of Tat into the VTAwas used in
the current study. Nevertheless, our results suggest that nicotine
and Tat synergistically affect CREB signaling throughout the
mesocorticolimbic system. Tat-induced decrease in CREB activity
negatively impact normal function of the mesocorticolimbic DA
system (Carlezon et al., 1998), which infers an increase in nicotine
award in Tat exposure animals.
Conclusion
HIV-1 Tat is critical to HIV-1 viral protein-induced alterations
of nicotine-mediated behavior and the phosphorylation levels
of ERK2 and CREB within the mesocorticolimbic system. The
current results suggest that a direct injection of Tat into the
VTA enhances basal levels of pERK1/2 in the VTA and NAc,
which may result in the low baseline locomotor activity observed
in intra-VTA Tat rats. The opposite effects of nicotine on
pERK1, pERK2, or pCREB in the VAT and NAc between the
intra-VAT Tat and intra-VAT vehicle groups may contribute
to the blunted behavioral sensitization to nicotine noted in
intra-VAT Tat rats. Determining how Tat influences the nicotine-
mediated ERK and CREB signaling in the mesocorticolimbic
system will provide insights into understanding molecular
mechanisms underlying a high cigarette smoking prevalence
among HIV-positive population.
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